New and Emerging Side Effects of Mounjaro: What You Should Know

What has changed in Mounjaro's safety guidance since launch?

Mounjaro carries a Black Triangle (▼) symbol, meaning the MHRA collects additional safety data as the medicine is used more widely. That process matters, because it catches signals that clinical trials (even large ones) can miss simply due to rarity.

The most significant regulatory update came on 29 January 2026, when the MHRA published a Drug Safety Update covering all GLP-1 receptor agonist medicines, including tirzepatide. It formally highlighted acute pancreatitis as a known but infrequent side effect that can become serious. The guidance asks prescribers and patients to be alert to severe, persistent stomach pain (particularly pain that travels through to the back, with or without vomiting) and to seek urgent medical attention rather than wait it out. This signal is not new to the pharmacology, but the 2026 update gave it sharper clinical prominence. You can read the full update on the MHRA Drug Safety Update index.

A second area of updated guidance concerns oral contraceptives. Because tirzepatide slows gastric emptying, it can reduce the absorption of medicines taken by mouth, including the pill. UK guidance now recommends adding a non-oral method (condoms, for example) for the first four weeks of treatment and for four weeks after every dose increase. This is specific to tirzepatide; the equivalent evidence for semaglutide is less clear-cut. Our Mounjaro side effects news page tracks these regulatory updates as they are published.

Are any new side effects being watched for as more people use the medicine?

There is a common misconception that once a medicine is licensed, its side-effect list is fixed. In practice, the list grows (or gets refined) as real-world use adds to trial data. With Mounjaro, a few areas remain under active monitoring.

Gallbladder events (gallstones, gallbladder inflammation) were seen at a low rate in trials and have since been flagged in prescriber information as a recognised risk, particularly with rapid weight loss. Rapid fat loss of any kind can raise bile concentration; this is not unique to GLP-1 medicines, but it is worth being aware of. Symptoms to watch for include pain under the right ribs, especially after eating fatty food.

Changes in mood or mental wellbeing are being monitored across GLP-1 medicines by regulators in several countries. The MHRA has not issued a specific signal for tirzepatide on this at the time of writing, but prescribers are encouraged to ask about mood, and patients are encouraged to mention any low mood or unusual thoughts. If you want a thorough breakdown of what the evidence currently shows, our page on Mounjaro side effects covers the full established list in detail, including less commonly discussed ones.

Injection-site reactions (redness, swelling, itching) are occasionally reported and, while rarely serious, are worth rotating injection sites consistently between the abdomen, thigh and upper arm to reduce the risk.

When should you get medical help, and what counts as urgent?

Most people experience side effects at the milder end, some nausea after a dose increase, a few unsettled days of digestion. Those tend to settle. The ones below are different and need medical attention promptly.

Call 999 or go to A&E if you have: severe stomach pain that does not ease and radiates to your back (possible pancreatitis); signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid heartbeat); sudden or severe vision changes if you have diabetes; signs of severe dehydration from prolonged vomiting or diarrhoea (extreme dizziness, very dark urine, inability to keep fluids down).

Contact your prescriber or GP as soon as you can if you notice: persistent upper abdominal pain even if mild; yellowing of the skin or eyes; a new lump or swelling in the neck area (relevant to the theoretical thyroid signal, which was observed in animal studies, the clinical significance in humans is unresolved but prescribers want to know); low mood, unusual thoughts or changes in mental health. If you experience persistent diarrhoea on Mounjaro, staying hydrated is the immediate priority and your prescriber should be informed.

The MHRA's Yellow Card scheme lets you report suspected side effects yourself, and those reports genuinely contribute to the ongoing monitoring that shapes future guidance. You do not need to be certain something is a side effect to report it.

How does understanding these side effects help before you start treatment?

Knowing what to expect (and what to watch for) is a practical safety tool, not a reason to avoid treatment. The weight-related health risks for people who qualify for Mounjaro are real, and for many people the benefit-risk balance is firmly positive.

What changes with good information is that you can act early. Nausea after stepping up to 5mg is expected and usually passes, and our guide to the 5 Mounjaro side effects people most commonly notice at that stage can help you tell the difference between what is normal and what warrants a call to your prescriber. That distinction is the kind of thing our prescribers talk through during the consultation.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, considers your full medical history, and can answer questions about how a side effect of Mounjaro or pre-existing conditions interact with treatment. If you want to explore whether Mounjaro is right for you, you can find out more about Mounjaro on our treatment page or look at our full weight loss treatment options. Our prescribers discuss suitability and likely side effects as part of every consultation, with no obligation to proceed. Find out how we work if you want to understand more about the service first.